Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Jan;55(1):77-85.
doi: 10.1002/hep.24706. Epub 2011 Dec 6.

Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease

Kris V Kowdley  1 , Patricia Belt, Laura A Wilson, Matthew M Yeh, Brent A Neuschwander-Tetri, Naga Chalasani, Arun J Sanyal, James E Nelson; NASH Clinical Research Network
Affiliations

Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease

Kris V Kowdley et al. Hepatology. 2012 Jan.

Abstract

Serum ferritin (SF) levels are commonly elevated in patients with nonalcoholic fatty liver disease (NAFLD) because of systemic inflammation, increased iron stores, or both. The aim of this study was to examine the relationship between elevated SF and NAFLD severity. Demographic, clinical, histologic, laboratory, and anthropometric data were analyzed in 628 adult patients with NAFLD (age, ≥ 18 years) with biopsy-proven NAFLD and an SF measurement within 6 months of their liver biopsy. A threshold SF >1.5 × upper limit of normal (ULN) (i.e., >300 ng/mL in women and >450 ng/mL in men) was significantly associated with male sex, elevated serum alanine aminotransferase, aspartate aminotransferase, iron, transferrin-iron saturation, iron stain grade, and decreased platelets (P < 0.01). Histologic features of NAFLD were more severe among patients with SF >1.5 × ULN, including steatosis, fibrosis, hepatocellular ballooning, and diagnosis of NASH (P < 0.026). On multiple regression analysis, SF >1.5 × ULN was independently associated with advanced hepatic fibrosis (odds ratio [OR], 1.66; 95% confidence interval [CI], 1.05-2.62; P = 0.028) and increased NAFLD Activity Score (NAS) (OR, 1.99; 95% CI, 1.06-3.75; P = 0.033).

Conclusions: A SF >1.5 × ULN is associated with hepatic iron deposition, a diagnosis of NASH, and worsened histologic activity and is an independent predictor of advanced hepatic fibrosis among patients with NAFLD. Furthermore, elevated SF is independently associated with higher NAS, even among patients without hepatic iron deposition. We conclude that SF is useful to identify NAFLD patients at risk for NASH and advanced fibrosis.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Histogram of distribution of serum ferritin values according to sex, above and below the threshold SF>1.5XULN
The relative proportion of subjects by serum ferritin values are shown for each of the four categories: A) SF≤1.5XULN, male; B) SF≤1.5XULN, female; C) SF>1.5XULN, male; D) SF>1.5XULN, female. Each bin corresponds to a range of SF values of 100ng/ml. The density estimation plot is shown by the smooth line.
Figure 2
Figure 2. Relationship between NAS, level of serum ferritin and presence and pattern of iron staining among subjects
The mean NAS values are shown for subjects above and below SF 1.5XULN according to each hepatic iron deposition pattern including subjects without iron deposition; HC, RES and mixed HC/RES groups. Significant differences between groups, determined using multivariate ordinal regression modeling after controlling for the covariates BMI, age, sex, type 2 diabetes and serum ALT level, are indicated by arrows. Standard deviations are indicated by the error bars.
See this image and copyright information in PMC

Comment in

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. McCullough AJ. The epidemiology and risk factors of NASH. In: Farrell GC, George J, de la Hall P, et al., editors. Fatty Liver Disease: NASH and Related Disorders Malden. MA: Blackwell Publishing; 2005. pp. 23–37.
    1. Arosio P, Ingrassia R, Cavadini P. Ferritins: A family of molecules for iron storage, antioxidation and more. Biochim Biophys Acta. 2009;1790:589–599. - PubMed
    1. Kalantar-Zadeh K, Rodriguez RA, Humphreys MH. Association between serum ferritin and measures of inflammation, nutrition and iron in haemodialysis patients. Nephrol Dial Transplant. 2004;19:141–149. - PubMed
    1. Konijn AM. Iron metabolism in inflammation. Baillieres Clin Haematol. 1994;7:829–849. - PubMed
    1. Ford ES, Cogswell ME. Diabetes and serum ferritin concentration among U.S. adults. Diabetes Care. 1999;22:1978–1983. - PubMed

Publication types

MeSH terms

Grants and funding